SAR445399
Sponsors
Sanofi-Aventis Recherche & Developpement, Sanofi
Conditions
Hidradenitis SuppurativaHidradenitis suppurativaNon-cystic Fibrosis BronchiectasisNon-cystic fibrosis bronchiectasis
Phase 2
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RecruitingNCT07225569
Start: 2025-12-29End: 2027-12-01Target: 144Updated: 2026-07-01
A randomized, double-blind, placebo-controlled, Phase 2, dose-finding study to investigate the efficacy and safety of SAR445399 in participants with moderate to severe hidradenitis suppurativa
Not yet recruitingCTIS2025-522695-83-00
Target: 39Updated: 2026-03-03
A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis
RecruitingNCT07547436
Start: 2026-06-08End: 2028-08-07Target: 70Updated: 2026-06-18
A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).
Not yet recruitingCTIS2025-523403-29-00
Target: 25Updated: 2026-06-24